S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc. ()|
|Synthetic Biologics Initiates Manufacturing of SYN-004 for Use in Preclinical and Clinical Trials to Target the Prevention of C. difficile Infections (2013/10/15)|
|Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update (2013/8/14)|
|Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update (2013/11/14)|
|Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs" (2013/9/20)|
|Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence (2013/11/14)|
|Synthetic Biologics and Intrexon Corporation Initiate Development of Novel Biologics for a Subset of Patients Suffering from Irritable Bowel Syndrome (IBS) (2013/12/9)|
|Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes (2013/12/7)|
|Synthetic Biologics' Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th (2013/12/9)|
|Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland (2013/9/10)|
Click above to view more mutual fund data and stats for syn - Synthetic Biologics Inc.